Acceleron Pharma Presents ACE-011 Preclinical Data Demonstrating Both Anabolic And Anti-Resorptive Properties; Novel Approach Represents Significant Advance For The Treatment Of Bone Loss

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 18, 2006--Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, presented preclinical data highlighting the anabolic bone activity of ACE-011, the company’s lead drug candidate currently in a phase 1 clinical trial, at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).